Utility of viral kinetics in HCV therapy – It is not over until it is over?

[1]  P. Rosenthal,et al.  American Association for the Study of Liver Diseases , 1993, IDrugs : the investigational drugs journal.

[2]  M. Dumont,et al.  European Association for the Study of the Liver , 1971 .

[3]  Jean-Michel Pawlotsky,et al.  EASL Recommendations on Treatment of Hepatitis C 2018. , 2018, Journal of hepatology.

[4]  P. Marcellin,et al.  Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays. , 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[5]  Robert Herring,et al.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. , 2014, The New England journal of medicine.

[6]  X. Forns,et al.  Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis , 2019, Liver international : official journal of the International Association for the Study of the Liver.

[7]  M. Stepanova,et al.  The impact of ledipasvir/sofosbuvir on patient‐reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[8]  M. Buti,et al.  Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. , 2018, Gastroenterology.

[9]  M. Manns,et al.  Eligibility and safety of the first interferon‐free therapy against hepatitis C in a real‐world setting , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[10]  M. Imamura,et al.  HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients , 2017, PloS one.

[11]  M. Manns,et al.  Drug-Drug Interactions With Novel All Oral Interferon-Free Antiviral Agents in a Large Real-World Cohort. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  M. Manns,et al.  Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. , 2016, Journal of hepatology.

[13]  Bing Li,et al.  Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study. , 2016, The lancet. Gastroenterology & hepatology.

[14]  Laetitia Canini,et al.  HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir. , 2016, Journal of hepatology.

[15]  M. Manns,et al.  Clinical significance of detectable and quantifiable HCV RNA at the end of treatment with ledipasvir/sofosbuvir in GT1 patients , 2018, Liver international : official journal of the International Association for the Study of the Liver.

[16]  A. Walker,et al.  Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. , 2016, Journal of hepatology.

[17]  B. Maasoumy,et al.  Diagnostics in hepatitis C: The end of response-guided therapy? , 2016, Journal of hepatology.

[18]  M. Buti,et al.  Strategies to manage hepatitis C virus (HCV) disease burden , 2014, Journal of viral hepatitis.